TY - JOUR T1 - Utility of Long-Term Cultured Human Hepatocytes as an in Vitro Model for Cytochrome P450 Induction JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 215 LP - 220 DO - 10.1124/dmd.106.009423 VL - 35 IS - 2 AU - Georgina Meneses-Lorente AU - Christine Pattison AU - Claire Guyomard AU - Christophe Chesné AU - Robert Heavens AU - Alan P. Watt AU - Bindi Sohal Y1 - 2007/02/01 UR - http://dmd.aspetjournals.org/content/35/2/215.abstract N2 - Cytochrome P450 (P450) induction may have considerable implications for drug therapy. Therefore, understanding the induction potential of a new chemical entity at an early stage in discovery is crucial to reduce the risk of failure in the clinic and help the identification of noninducing chemical structures. Availability of human viable tissue often limits evaluation of induction potential in human hepatocytes. A solution is to increase the time period during which the hepatocytes remain viable. In this study we have investigated the induction of several P450 isozymes in long-term cultured hepatocytes compared with short-term cultured hepatocytes from the same individuals. Short- and long-term cultured primary hepatocytes isolated from each individual were cultured in a 96-well format and treated for 24 h with a range of prototypical P450 inducers and Merck Research Laboratories compounds. CYP3A4, 1A1, 1A2, 2B6, and 2C9 mRNA levels were measured using quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan) from the same cultured hepatocyte wells. CYP3A4, 1A1, 1A2, 2B6, and 2C9 were shown to be inducible in long-term cultured hepatocytes. The -fold induction varied between donors, and between short- and long-term cultured hepatocytes from the same donor. However, this variability can be controlled by normalizing data from each hepatocyte preparation to a positive control. The use of long-term cultured hepatocytes on 96-well plates has proven to be sensitive, robust, and convenient for assessing P450 induction potential of new compound entities during the drug discovery process. The American Society for Pharmacology and Experimental Therapeutics ER -